Literature DB >> 26351330

Immunology and Immunotherapy of Head and Neck Cancer.

Robert L Ferris1.   

Abstract

The immune system plays a key role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of HNSCC provides the basis for improved therapies and outcomes for patients. HNSCC cells evade the host immune system through manipulation of their own immunogenicity, production of immunosuppressive mediators, and promotion of immunomodulatory cell types. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. This article provides a brief overview of key components of the immune infiltrating cells in the tumor microenvironment, reviewing immunological principles related to head and neck cancer, including the concept of cancer immunosurveillance and immune escape. Current immunotherapeutic strategies and emerging results from ongoing clinical trials are presented.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2015        PMID: 26351330      PMCID: PMC4586169          DOI: 10.1200/JCO.2015.61.1509

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  101 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Epidemiology of head and neck squamous cell cancer among HIV-infected patients.

Authors:  Gypsyamber Dʼsouza; Thomas E Carey; William N William; Minh Ly Nguyen; Eric C Ko; James Riddell; Sara I Pai; Vishal Gupta; Heather M Walline; J Jack Lee; Gregory T Wolf; Dong M Shin; Jennifer R Grandis; Robert L Ferris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

3.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 4.  TGF-beta and tumors--an ill-fated alliance.

Authors:  Niki M Moutsopoulos; Jie Wen; Sharon M Wahl
Journal:  Curr Opin Immunol       Date:  2008-05-15       Impact factor: 7.486

5.  SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Authors:  Michael S Leibowitz; Raghvendra M Srivastava; Pedro A Andrade Filho; Ann Marie Egloff; Lin Wang; Raja R Seethala; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

6.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A S Pak; M A Wright; J P Matthews; S L Collins; G J Petruzzelli; M R Young
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

7.  Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.

Authors:  Yaping Sun; Y Eugene Chin; Elizabeth Weisiger; Chelsea Malter; Isao Tawara; Tomomi Toubai; Erin Gatza; Paolo Mascagni; Charles A Dinarello; Pavan Reddy
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

8.  Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck.

Authors:  Deanne M R Lathers; M Rita I Young
Journal:  Cytokine       Date:  2004-03-07       Impact factor: 3.861

9.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

10.  Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation.

Authors:  Emanuela I Sega; Dennis B Leveson-Gower; Mareike Florek; Dominik Schneidawind; Richard H Luong; Robert S Negrin
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  212 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

2.  Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Authors:  Sonja Ludwig; Theofanis Floros; Marie-Nicole Theodoraki; Chang-Sook Hong; Edwin K Jackson; Stephan Lang; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

3.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Authors:  Gulidanna Shayan; Raghvendra Srivastava; Jing Li; Nicole Schmitt; Lawrence P Kane; Robert L Ferris
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

4.  Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.

Authors:  Guang-Tao Yu; Liang Mao; Lei Wu; Wei-Wei Deng; Lin-Lin Bu; Jian-Feng Liu; Lei Chen; Lei-Lei Yang; Hao Wu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Cell Mol Life Sci       Date:  2018-06-28       Impact factor: 9.261

5.  Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.

Authors:  Lei Chen; Cong-Fa Huang; Yi-Cun Li; Wei-Wei Deng; Liang Mao; Lei Wu; Wen-Feng Zhang; Lu Zhang; Zhi-Jun Sun
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

6.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

7.  Investigation of immune cell markers in feline oral squamous cell carcinoma.

Authors:  Ellen E Sparger; Brian G Murphy; Farina Mustaffa Kamal; Boaz Arzi; Diane Naydan; Chrisoula T Skouritakis; Darren P Cox; Katherine Skorupski
Journal:  Vet Immunol Immunopathol       Date:  2018-06-13       Impact factor: 2.046

Review 8.  Emerging role of circulating tumor cells in immunotherapy.

Authors:  Alexey Rzhevskiy; Alina Kapitannikova; Polina Malinina; Arthur Volovetsky; Hamidreza Aboulkheyr Es; Arutha Kulasinghe; Jean Paul Thiery; Anna Maslennikova; Andrei V Zvyagin; Majid Ebrahimi Warkiani
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

9.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

10.  PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Authors:  Benjamin A Kansy; Fernando Concha-Benavente; Raghvendra M Srivastava; Hyun-Bae Jie; Gulidanna Shayan; Yu Lei; Jessica Moskovitz; Jennifer Moy; Jing Li; Sven Brandau; Stephan Lang; Nicole C Schmitt; Gordon J Freeman; William E Gooding; David A Clump; Robert L Ferris
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.